<div class="headers"><div>Fig. 1 Patients reporting no enthesitis (a) and no dactylitis (b) at week 24. Integrated analysis set with baseline enthesitis and dactylitis are shown as the percentages of responders (95% Cl, NRI). *P vs PBO < 0.05; **P vs PBO < 0.001. Abbreviations: Achill tend insert, Achilles tendon insertion; Cl, confidence interval; IXEQ2W, ixekizumab 80 mg every 2 weeks; IXEQ4W, ixekizumab 80 mg every 4 weeks; Lat epicond, lateral epicondyle; LEI, Leeds Enthesitis Index; LDI-B, Leeds Dactylitis Index-Basic; Med fern cond, medial femoral condyle; NRI, nonresponder imputation; PBO, placebo</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; border-bottom: 2px solid grey; text-align: left;'><p style="" class="">Fig. 1 Patients reporting no enthesitis (a) and no dactylitis (b) at week 24. Integrated analysis set with baseline enthesitis and dactylitis are shown as the percentages of responders (95% Cl, NRI). *P vs PBO < 0.05; **P vs PBO < 0.001. Abbreviations: Achill tend insert, Achilles tendon insertion; Cl, confidence interval; IXEQ2W, ixekizumab 80 mg every 2 weeks; IXEQ4W, ixekizumab 80 mg every 4 weeks; Lat epicond, lateral epicondyle; LEI, Leeds Enthesitis Index; LDI-B, Leeds Dactylitis Index-Basic; Med fern cond, medial femoral condyle; NRI, nonresponder imputation; PBO, placebo</p></td>
</tr>
</tbody>
</table>
